Hallman H, Jonsson G
Eur J Pharmacol. 1984 Aug 17;103(3-4):269-78. doi: 10.1016/0014-2999(84)90487-4.
Systemic treatment with the noradrenaline neurotoxin DSP4 (N-[2-chloroethyl]-N-ethyl-2-bromobenzylamine; 7 days) led to a marked and quantitatively similar reduction (-80%) of endogenous noradrenaline, [3H]noradrenaline uptake in vitro and [3H]desipramine binding in the frontal cortex of adult rats. Inhibition of monoamine oxidase, and/or 1-dopa administration 1 week after DSP4 produced very small changes in brain noradrenaline and dopamine levels. These results are all consistent with the view that DSP4 produces an acute and selective degeneration of central noradrenaline nerve terminals. Pretreatment with the noradrenaline uptake blocker desipramine prevented the action of DSP4 almost completely, while treatment after DSP4 had minute effects on DSP4-induced reduction of endogenous noradrenaline and [3H]noradrenaline uptake. The data suggest that the irreversible neurotoxic actions of DSP4 are very rapid and largely complete within 0.5 h after DSP4 administration. Measurement of catecholamine turnover using monoamine oxidase inhibition by pargyline indicated an increased noradrenaline turnover in the remaining nerve terminals innervating cerebral cortex and hippocampus after DSP4, while dopamine turnover appeared to be decreased. Pretreatment with d-amphetamine and clonidine or subsequent treatment with oxotremorine were without effect on the DSP4-induced reductions of the regional brain noradrenaline levels. Morphine pretreatment was also ineffective, while repeated morphine administration after DSP4 produced a significant potentiation of the DSP4-induced noradrenaline depletion in the frontal cortex, cerebellum and the spinal cord. Pretreatment with the monoamine oxidase inhibitor pargyline led to a very pronounced counteraction of the DSP4-induced noradrenaline depletion in all brain regions analysed, in particular in the occipital cortex. The data suggest that morphine can potentiate the neurotoxic action of DSP4 while pargyline can counteract it.
用去甲肾上腺素神经毒素DSP4(N-[2-氯乙基]-N-乙基-2-溴苄胺;7天)进行全身治疗,导致成年大鼠额叶皮质内源性去甲肾上腺素、体外[3H]去甲肾上腺素摄取和[3H]地昔帕明结合显著且在数量上相似地减少(-80%)。DSP4给药1周后,单胺氧化酶的抑制和/或左旋多巴的给药对脑内去甲肾上腺素和多巴胺水平产生的变化非常小。这些结果均与DSP4引起中枢去甲肾上腺素神经末梢急性和选择性变性的观点一致。用去甲肾上腺素摄取阻滞剂地昔帕明预处理几乎完全阻止了DSP4的作用,而在DSP4给药后进行治疗对DSP4诱导的内源性去甲肾上腺素减少和[3H]去甲肾上腺素摄取的影响很小。数据表明,DSP4的不可逆神经毒性作用非常迅速,在给药后0.5小时内基本完成。使用帕吉林抑制单胺氧化酶来测量儿茶酚胺周转率表明,DSP4给药后,支配大脑皮质和海马体的剩余神经末梢中去甲肾上腺素周转率增加,而多巴胺周转率似乎降低。用右旋苯丙胺和可乐定预处理或随后用氧化震颤素治疗对DSP4诱导的区域脑去甲肾上腺素水平降低没有影响。吗啡预处理也无效,而在DSP4给药后重复给予吗啡会显著增强DSP4诱导的额叶皮质、小脑和脊髓去甲肾上腺素耗竭。用单胺氧化酶抑制剂帕吉林预处理导致在所有分析的脑区中,尤其是枕叶皮质,对DSP4诱导的去甲肾上腺素耗竭有非常明显的对抗作用。数据表明,吗啡可增强DSP4的神经毒性作用,而帕吉林可对抗这种作用。